

EQA round: ALB2/23 - Albumin in Urine

Deadline: 13.10.2023

Setup: groups - manufacturer of kit; minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N_{tot} = total number of the resultsN_{out} = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U_{AV} = expanded uncertainty of the assigned value (k = 2)D_{max} = acceptable difference

LL = lower limit

UL = upper limit

N_{eva} = number of the results assessedN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
(470) ACR	[g/mol]				242							242	213	88	
Sample A												242	216	89	
(0) not specified		2,47	0,33	13	242	0	CVP	2,47	0,051	30%	1,72	3,22	242		
Sample B												242	237	98	
(0) not specified		4,65	0,43	9,3	242	0	CVP	4,65	0,068	24%	3,53	5,77	242		
(369) Albumin	[mg/L]				251							251	229	91	
Sample A		14,6	1,5	10	251		CVP	14,6	0,23	30%	10,2	19	251	232	92
(1) Abbott		15,9	1,1	6,7	67	0							67		
(58) Beckman Coulter (AU)		14,4	0,94	6,6	37	0							37		
(60) Roche		14,5	0,77	5,3	91	0							91		
(149) Siemens (Dade, BN, Dimension)		16,1	0,22	1,4	5	0							5		
(162) Siemens (Atellica)		9,91	1	10	18	0							18		
(179) Siemens		11	1,1	10	12	0							12		
Other					21	0							21		
								1x 0, 1x 5, 4x 12, 1x 36, 1x 46, 1x 49, 1x 73, 2x 75, 1x 116, 3x 152, 3x 177, 2x 178							
Sample B		58,7	4,1	6,9	251		CVP	58,7	0,63	21%	46,3	71,1	251	247	98
(1) Abbott		61,2	3	4,9	67	0							67		
(58) Beckman Coulter (AU)		59,3	2,7	4,5	37	0							37		
(60) Roche		57,4	2,5	4,4	91	0							91		
(149) Siemens (Dade, BN, Dimension)		66	1,9	2,8	5	0							5		
(162) Siemens (Atellica)		53,2	1,5	2,8	18	0							18		
(179) Siemens		56,5	5	8,9	12	0							12		
Other					21	0							21		
								1x 0, 1x 5, 4x 12, 1x 36, 1x 46, 1x 49, 1x 73, 2x 75, 1x 116, 3x 152, 3x 177, 2x 178							
(408) Creatinine	[mmol/L]				243							243	241	99	
Sample A		5,92	0,28	4,8	243		CVP	5,92	0,044	16%	4,97	6,87	243	242	100
(1) Abbott		5,75	0,16	2,8	62	0							62		
(46) Erba Lachema		6,02	0,12	2	7	0							7		
(58) Beckman Coulter (AU)		5,88	0,4	6,7	40	0							40		
(60) Roche		6	0,26	4,3	88	0							88		
(162) Siemens (Atellica)		5,96	0,21	3,6	20	0							20		
(179) Siemens		6,17	0,27	4,3	12	0							12		
Other					14	0							14		
								3x 0, 2x 5, 1x 12, 1x 73, 1x 116, 1x 149, 1x 158, 2x 177, 2x 178							
Sample B		12,6	0,53	4,2	243		CVP	12,6	0,083	16%	10,5	14,7	243	241	99
(1) Abbott		12,3	0,36	2,9	62	0							62		
(46) Erba Lachema		12,9	0,15	1,1	7	0							7		
(58) Beckman Coulter (AU)		12,7	0,52	4,1	40	0							40		
(60) Roche		12,7	0,52	4,1	88	0							88		
(162) Siemens (Atellica)		12,6	0,43	3,4	20	0							20		
(179) Siemens		12,9	0,26	2	12	0							12		
Other					14	0							14		
								3x 0, 2x 5, 1x 12, 1x 73, 1x 116, 1x 149, 1x 158, 2x 177, 2x 178							